Filing Flows

Filing Flows › Intellia Therapeutics (NTLA) › Who owns the stock

Who owns Intellia Therapeutics (NTLA) stock

315 funds reported Intellia Therapeutics (NTLA) shares in their latest 13F filings, worth $2.5B in all. The largest holder is ARK Investment Management LLC ($286M). Last quarter 176 funds added to their stakes and 99 cut them.

Largest holders of NTLA (13F)Largest holders of NTLA (13F)ARK Investment Management LLC$286MBlackRock$261MState Street$156MVanguard Portfolio Management LLC$124MVanguard Group$117MD. E. Shaw$109MVanguard Capital Management LLC$102MTwo Sigma Investments, LP$88.6MFMR LLC$80.8MRA Capital Management, L.P.$76.6M

Largest holders (13F)

FundSharesValueChangeQuarter
ARK Investment Management LLC16,875,684$286Mincrease2026-06-30
BlackRock15,409,023$261Mincrease2026-06-30
State Street9,234,987$156Mincrease2026-06-30
Vanguard Portfolio Management LLC7,332,401$124Mincrease2026-06-30
Vanguard Group13,010,001$117Mincrease2025-12-31
D. E. Shaw6,443,323$109Mincrease2026-06-30
Vanguard Capital Management LLC6,028,586$102Mincrease2026-06-30
Two Sigma Investments, LP5,235,348$88.6Mincrease2026-06-30
FMR LLC4,773,034$80.8Mincrease2026-06-30
RA Capital Management, L.P.4,526,926$76.6Mnew2026-06-30
Regeneron Pharmaceuticals3,702,995$62.7Munchanged2026-06-30
Geode Capital Management, LLC3,631,061$61.4Mincrease2026-06-30
Arrowstreet Capital, Limited Partnership3,280,760$55.5Mincrease2026-06-30
Nikko Asset Management Americas2,897,529$49.0Mincrease2026-06-30
Sumitomo Mitsui Trust Group2,897,529$49.0Mincrease2026-06-30

Intellia Therapeutics' latest quarter

Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most NTLA stock?

By the latest 13F filings: ARK Investment Management LLC ($286M); BlackRock ($261M); State Street ($156M); Vanguard Portfolio Management LLC ($124M); Vanguard Group ($117M).

What is the short interest in NTLA?

44,435,219 shares were sold short at the 2026-10-15 settlement, -1.5% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.